Literature DB >> 23746422

The effects of adjunctive parathyroid hormone injection on bisphosphonate-related osteonecrosis of the jaws: an animal study.

E H Dayisoylu1, F Ç Şenel, C Üngör, E Tosun, M Çankaya, S Ersöz, F Taskesen.   

Abstract

Bisphosphonate (BP)-related osteonecrosis of the jaw (BRONJ) is a serious and challenging complication of chronic BP uptake in patients with osteoporosis who require management of skeletal-related events. The efficiency of adjunctive parathyroid hormone (PTH) injection was evaluated after chronic BP administration that was followed by tooth extraction. BRONJ was not observed in any of the subjects in the control groups, while BRONJ was observed in 66% and 22% of the subjects in the tooth extraction group and the tooth extraction with PTH injection group, respectively. In addition the presence and severity of inflammation was lower in the PTH injected group than in the tooth extraction group, but the difference was not statistically significant (P>0.01). In conclusion, the administration of 30μg/kg/day PTH during a period of 8 weeks had positive effects on the resolution of BRONJ, but further studies are required to verify the effectiveness of PTH in the treatment of BRONJ. Crown
Copyright © 2013. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  animal model; bisphosphonate-related osteonecrosis of the jaw; parathyroid hormone; teriparatide

Mesh:

Substances:

Year:  2013        PMID: 23746422     DOI: 10.1016/j.ijom.2013.05.001

Source DB:  PubMed          Journal:  Int J Oral Maxillofac Surg        ISSN: 0901-5027            Impact factor:   2.789


  14 in total

1.  A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration.

Authors:  Y Ohbayashi; A Iwasaki; F Nakai; T Mashiba; M Miyake
Journal:  Osteoporos Int       Date:  2019-11-25       Impact factor: 4.507

Review 2.  Interventions for treating bisphosphonate-related osteonecrosis of the jaw (BRONJ).

Authors:  Victoria Rollason; Alexandra Laverrière; Laura C I MacDonald; Tanya Walsh; Martin R Tramèr; Nicole B Vogt-Ferrier
Journal:  Cochrane Database Syst Rev       Date:  2016-02-26

Review 3.  Anabolic agents: what is beyond osteoporosis?

Authors:  Y Liu; A E Levack; E Marty; O Or; B P Samuels; M Redko; J M Lane
Journal:  Osteoporos Int       Date:  2018-04-07       Impact factor: 4.507

4.  The effect of laser therapy on the expression of osteocalcin and osteopontin after tooth extraction in rats treated with zoledronate and dexamethasone.

Authors:  Giovanni Mergoni; Paolo Vescovi; Roberto Sala; Elisabetta Merigo; Pietro Passerini; Roberta Maestri; Domenico Corradi; Paolo Govoni; Samir Nammour; Massimiliano G Bianchi
Journal:  Support Care Cancer       Date:  2015-07-21       Impact factor: 3.603

5.  Standardized Arrabidaea chica Extract Shows Cytoprotective Effects in Zoledronic Acid-Treated Fibroblasts and Osteoblasts.

Authors:  Patricia Maria Wiziack Zago; Ilza Maria Oliveira Sousa; Leila Servat-Medina; Michelle Pedroza Jorge; Lidio Gonçalves Lima Neto; Viviane Hass; Xin Li; Ana Lucia Tasca Gois Ruiz; Deepak Saxena; Mary Ann Foglio
Journal:  Clin Cosmet Investig Dent       Date:  2020-08-11

Review 6.  Pathophysiology of Osteonecrosis of the Jaws.

Authors:  Tara Aghaloo; Renna Hazboun; Sotirios Tetradis
Journal:  Oral Maxillofac Surg Clin North Am       Date:  2015-09-26       Impact factor: 2.802

Review 7.  Preclinical models of medication-related osteonecrosis of the jaw (MRONJ).

Authors:  J I Aguirre; E J Castillo; D B Kimmel
Journal:  Bone       Date:  2021-09-11       Impact factor: 4.398

Review 8.  Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.

Authors:  Athanasios D Anastasilakis; Jessica Pepe; Nicola Napoli; Andrea Palermo; Christos Magopoulos; Aliya A Khan; M Carola Zillikens; Jean-Jacques Body
Journal:  J Clin Endocrinol Metab       Date:  2022-04-19       Impact factor: 6.134

Review 9.  Pathogenesis of medication-related osteonecrosis of the jaw: a comparative study of in vivo and in vitro trials.

Authors:  Henrik Holtmann; Julian Lommen; Norbert R Kübler; Christoph Sproll; Majeed Rana; Patrick Karschuck; Rita Depprich
Journal:  J Int Med Res       Date:  2018-08-09       Impact factor: 1.671

10.  Enhancement of peri-implant bone formation via parathyroid hormone administration in a rat model at risk for medication-related osteonecrosis of the jaw.

Authors:  Ji Young Park; Hyun A Heo; Suhyun Park; Sung Woon Pyo
Journal:  J Periodontal Implant Sci       Date:  2020-03-19       Impact factor: 2.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.